Reset Map13 Results
2001 Production Drive Suite 1-3 Louisville, kentucky, 40299 United StatesCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
8 & 9 Old Station Business Park Compton , Berkshire, RG20 6NE United KingdomCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
Campus Vienna Biocenter II Viehmarktgasse 2A Vienna, 1030 AustriaCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
Nobelova 34 Bratislava , Bratislava , 836 05 SlovakiaCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
Building D80 Robert-Roessle-Strasse 10 Berlin, 13125 GermanyCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
Zuidersluisweg 2 Lelystad, 8243 RC NetherlandsCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
4-9 Old Station Business Park Compton, Berkshire, RG20 6NE United KingdomCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
Rietlistrasse 4 Staad , SG 9422 SwitzerlandCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
Belasis Court Billingham, England, TS23 4 United KingdomCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
7887 Dunbrook Rd Suite F San Diego, CA, 92126 United StatesCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
Zub lane 65 Gardner, MA, 01440 United StatesCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
2001 Production Drive Suite 1-3 Louisville, KY, 40299 United StatesCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
17-18 Belasis Court Belasis Hall Technology Park Billingham, Cleveland, TS23 4AZ United KingdomCritical Raw Materials and Services for Life Science and Diagnostics form R&D to GMP. Working across modalities, Biosynth provides a comprehensive set of problem-solving services and high quality products to help customers develop new therapies and diagnostics. Biosynth Life Sciences provides expert services in small molecule manufacturing, bioconjugate and advanced polymer manufacture alongside complex peptide discovery and supply. These services pair with product specialties for high quality ongoing supply of bioprocess reagents and critical materials for the oligonucleotide supply chain. Biosynth Diagnostics provides the leading diagnostics companies with critical materials including antigens and antibodies, innovative small molecule substrates and serum and plasma. This is complemented by an expanding collection of readily available products and custom projects to create recombinant proteins and enzymes, and complex peptides to replace proteins across assays. Key Capabilities and Expertise Biosynth is built around a specialist cross modality offering, delivering a comprehensive range of products and services. That’s why we offer a high-touch, expert-led partnership designed to move your science forward—faster. With decades of hands-on experience across modalities, our team becomes an extension of yours. We don’t just provide services—we bring strategic insight, scientific rigor, and operational agility to every stage of your pipeline. From practical to pioneering, we help you navigate complexity, reduce risk, and accelerate timelines—so that life-changing therapies and diagnostics can help patients sooner. Biosynth History Biosynth was founded in 1966, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleosides and enzyme substrates. In 2022 the company returned to the Biosynth brand, and embarked on a period of expansion and acquisition. The Biosynth Group acquired a number of companies from then on, including vivitide, Pepscan, Aalto Bio Reagents, EUCODIS Bioscience, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB), celares, Pepceuticals, and VIO Chemicals. For more information please visit our website: https://www.biosynth.com/
Site Information
The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.
We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.
Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.
Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.
What is Scientist.com?
Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.
How can I use Scientist.com?
Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at support@scientist.com or go to our website www.scientist.comto speak to someone via our live chat.
Why should I place my order through Scientist.com?
Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.
How do I get my organization listed on the map?
If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.
Information about my organization is incorrect, how do I fix it?
Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.